Advisory Board Member
Richard has been a private investor in healthcare companies for many years and served as a Senior Manager at Bridgewater Associates, the world’s largest hedge fund with $140B in global assets.
Formerly held the positions of:
- CEO MolecularWare (bioinformatics) MIT Spinout
- CEO TheraGentics (pharmacogenetics) Kings College London Spinout
- Chairman Rhapsody Biologics (vaccine development platform) Singapore
- Board Member Rexahn Pharma (public US company)
Other relevant experience and expertise
Has built multiple companies in the biotech, diagnostic and personalized medicine space in the US Europe and Singapore. Relationships with leading Pharma and Biotech companies as well as leading venture capital groups.
Bioinformatics, Genetics, Personalized Medicine, Biomarker discovery and development. Regulatory strategy
Serves as a lecturer on Personized medicine and Global Pharma, as finance and entrepreneurship at MIT as well as Skolkovo Business school in Moscow.
Trustee of Fundación Innovación Bankinter, Madrid Spain